Kamada Ltd. (NASDAQ:KMDA) Short Interest Up 8.9% in November

Kamada Ltd. (NASDAQ:KMDA) was the recipient of a large growth in short interest in November. As of November 15th, there was short interest totalling 29,300 shares, a growth of 8.9% from the October 31st total of 26,900 shares. Based on an average trading volume of 34,400 shares, the short-interest ratio is currently 0.9 days. Approximately 0.1% of the shares of the company are sold short.

Kamada Price Performance

KMDA opened at $5.99 on Tuesday. The business has a 50 day moving average price of $5.58 and a two-hundred day moving average price of $5.48. The company has a market capitalization of $344.31 million, a price-to-earnings ratio of 21.39 and a beta of 0.99. Kamada has a 1-year low of $4.66 and a 1-year high of $6.53.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on KMDA. HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of Kamada in a report on Thursday, November 14th. StockNews.com lowered shares of Kamada from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 27th.

Institutional Trading of Kamada

Several institutional investors have recently modified their holdings of KMDA. Public Employees Retirement System of Ohio acquired a new position in Kamada during the third quarter worth about $77,000. Plato Investment Management Ltd acquired a new stake in Kamada in the 3rd quarter valued at about $117,000. Y.D. More Investments Ltd boosted its position in shares of Kamada by 1,956.0% during the 2nd quarter. Y.D. More Investments Ltd now owns 726,161 shares of the biotechnology company’s stock valued at $3,643,000 after purchasing an additional 690,842 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Kamada by 8.2% in the 1st quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock worth $7,433,000 after purchasing an additional 100,800 shares during the last quarter. Institutional investors and hedge funds own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.